ClinicalTrials.gg
Enrolling by invitationNCT06219291Updated Jan 23, 2024

Preventing the Progression of Multiple Sclerosis: Early Rehabilitative Treatment and Multimodal Assessment - Part A

An observational study in Multiple Sclerosis, sponsored by Fondazione Don Carlo Gnocchi Onlus. Enrolling by invitation at 3 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by Fondazione Don Carlo Gnocchi Onlus · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Multiple Sclerosis by Fondazione Don Carlo Gnocchi Onlus — 7 open to participants now, 8 under way, none of them phase 3. Multiple Sclerosis · Fondazione Don Carlo Gnocchi Onlus.

Started
2022
with 2 others
Observational
4 of 25
3 open now
Registered
21st of 25
by date

Among the 25 studies in Multiple Sclerosis by Fondazione Don Carlo Gnocchi Onlus, this one is one of 3 that started in 2022, is one of 4 observational ones, and was the 21st registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

7 of the 25 studies in Multiple Sclerosis by Fondazione Don Carlo Gnocchi Onlus are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Multiple Sclerosis by Fondazione Don Carlo Gnocchi Onlus, or all of them as a file.
02

Study summary

Motor performance of people with Multiple Sclerosis (PwMS) can decline since the onset of the disease.

Longitudinal studies are needed to detect early worsening in mobility and balance using wearable devices for activity tracking and neurophysiological techniques for investigating brain functional adaptation. Similarly, neurophysiological assessment can provide evidences on the integrity of brain motor networks and mechanisms underlying cortical plasticity in the early disease phase, potentially providing a set of reliable prognostic factors of disease progression in early diagnosed PwMS.

Furthermore, disease progression might be delayed using physical activity, which is effective in PwMS with moderate disability to ameliorate mobility and promoting brain reorganization and seems promising also for PwMS in the early stages of the disease. Functional Near-Infrared Spectroscopy (fNIRS) measures blood flow which accompanies neuronal activity, thus, it can provide spatial information about changes in cortical activation patterns and it could represent a useful tool for studying the effect of exercise on cortical plasticity. The aims of the study in non-disabled PwMS are: 1) a) to assess the presence of subclinical balance and walking impairments using wearable devices and multimodal gait analysis and b) to investigate cortical activity during exercise, 2) to define prognostic factors associated to disease progression and 3) to study the efficacy of physical activity in preventing the worsening of mobility and stimulating brain functional adaptation.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • early phase
  • non-disabled
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited within Persons with Multiple Sclerosis attending the clinical centers for routine medical visits willing to participate to the study after the presentation of the information sheet.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 17 years
  • Stable disease course (without worsening over 1 point at the EDSS in the last 3 months)
  • Expanded Disability Status Scale (EDSS) \<2.5

Exclusion criteria

Exclusion Criteria:

  • Major depression
  • \< 27
  • Other cardiovascular or orthopedic diseases that interfere with physical exercise
  • Undefined or not confirmed diagnosis of MS (Polman criteria)
  • Progressive course of the disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Interventions

  • OtherObservational

    Observation of the natural course of the disease

06

What researchers measure

Primary outcomes

  1. Six Minute Walk test (SMWT)

    Assesses distance in meters walked over 6 minutes as a sub-maximal test of endurance capacity.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

Secondary outcomes

  1. Concentration of oxygenated hemoglobin (Delta oxyHb)

    The differences in oxyHb during task period and resting state. Data will be extracted from functional Near InfraRed Spectroscopy (fNIRS) assessment.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  2. Expanded Disability Status Scale (EDSS)

    Assess the neurological impairment as a result of Multiple Sclerosis, ranging from 0 (normal neurological exam) to 10 (death due to Multiple Sclerosis).

    Time frame: Baseline, Follow up 1year, Follow up 2year

  3. Regularity of gait

    Instrumental gait indexes will be extracted from an Inertial Measurement Unit (IMU) during the a walking test.

    Time frame: Baseline, Follow-up 1year, Follow-up 2yearr

Other outcomes

  1. Dual Task Cost

    The physical and mental cost of the contemporary execution of two tasks will be evaluated with a specific test (walking and counting backwards). The dual-task cost quantifies this interference and is the percentage change of dual-task (DT) performance compared with single-task performance. Moreover, we will assess the patients' perspective on the perceived difficulties of dual-tasking during daily activities through the Dual-task Impact on Daily-living Activities Questionnaire (DIDA-Q). The questionnaire is composed by 19 items. It provides a global score ranging on a 0-76 scale and three subscale scores identifying the components mostly contributing to the perceived difficulty in DT activities: balance and mobility (6 items, score range 0-24), cognition (8 items, score range 0-32) and upper-limb ability (5 items, score range 0-20). Higher scores represent greater difficulties in performing dual task activities.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  2. Dual-task Impact on Daily-living Activities Questionnaire (DIDA-Q)

    Investigators will assess the patients' perspective on the perceived difficulties of dual-tasking during daily activities through the Dual-task Impact on Daily-living Activities Questionnaire (DIDA-Q). The questionnaire is composed by 19 items. It provides a global score ranging on a 0-76 scale and three subscale scores identifying the components mostly contributing to the perceived difficulty in DT activities: balance and mobility (6 items, score range 0-24), cognition (8 items, score range 0-32) and upper-limb ability (5 items, score range 0-20). Higher scores represent greater difficulties in performing dual task activities.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  3. Timed 25 foot walk (T25FWT)

    Evaluation of gait velocity (m/s) derived from the time taken to cover a distance of 25 foot.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  4. Fullerton Advanced Balance Scale - Short version (FAB-s)

    A test to evaluate static and dynamic balance composed by 8 tasks. Each task is rated from 0 (impossible) to 4 (normal execution). Higher values represent better balance capacity.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  5. Explosive power

    To evaluate explosive power capacity, subjects will execute bipodalic squat and counter-movement jumps (mono e bipodalic) wearing an IMU (g-Walk, BTS). Data regarding jump height, power, velocity and force will be extracted through the dedicated software (Baiobit, BTS).

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  6. Tactile sensitivity (Monofilament Test)

    Monofilament test will be applied to the eminence of the distal phalanx of the hallux to test levels of touch sensitivity of the foot. The patient close his eyes and say "yes" every time touch is felt. The level of sensitivity is determined by the smallest monofilament felt correctly for three times. Level of sensitivity thus will be classified from loss of deep protective sensation to normal light touch.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  7. Nine Hole peg Test (NHPT)

    A measure to assess fine dexterity.Is administered by asking the client to take the pegs from a container, one by one, and place them into holes on the board as quickly as possible. Participants must then remove the pegs from the holes, one by one, and replace them back into the container. Scores are based on the time taken to complete the activity, recorded in seconds. Normal scores are around 18 seconds.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  8. The revised Brief Visuospatial Memory Test (BVMTR):

    Is a measure of visual memory ability. Six abstract designs are presented for 10 sec and patients render the stimuli. Each design receives from 0 to 2 points representing accuracy and location. The test is repeated 3 times and the final scores is the sum of the three trials.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  9. California Verbal Learning Test (CVLT2):

    It measures verbal memory ability. Patients listen to a 16 list of word and report as many of the items as possible. There are five learning trials. The total score is the total number of recalled items over the five learning trials.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  10. Symbol Digit Modalities Test (SDMT)

    It assesses mental processing speed. It presents a series of nine symbols, paired with a single digit. Patients are asked to voice the digit associated with each symbol for 90 sec. The scores is the number correct over the 90 sec time span.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  11. Multiple Sclerosis Walking Scale 12 (MSWS-12)

    Is a self-report measure of the impact of Multiple Sclerosis on the individual's walking ability. The scoring provides options 1-5 for each item, with 1 meaning no limitation and 5 meaning extreme limitation on the gait-related item.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  12. Fatigue Severity Scale (FSS)

    Is a 9-item self-administered questionnaire to measure the perceived impact of fatigue. The minimum score is 9 and maximum score possible is 63. Higher scores represent greater fatigue severity. If the score is calculated as the mean score of the 9 items, the cut-off score for the presence of the symptom fatigue is set as scores higher than 4.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  13. Community Integration Questionnaire (CIQ)

    Is a self-administered questionnaire used to assess the social role limitations and community interactions. Score ranges from 0 (no integration) to 29 (full participation).

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  14. Hospital Anxiety and Depression Scale (HADS)

    A questionnaire to detect the presence of anxiety and depression. Subscores are calculated for anxiety and depression ranging from 0 (normal) to 21 (abnormal) with a cut-off score of 8.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  15. Lifetime Total Physical Activity Questionnaire (LTPAQ)

    is an interviewer-administered questionnaire used to estimate a respondent's physical activity done from childhood to the present in terms of months, days and hours. Data will be compared to normative values collected from a comparable sample of healthy subjects.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

  16. Amount of physical activity

    Subjects will be monitored for 1 week wearing an actigraph (GENEActiv). Actigraphy is a non-invasive method of monitoring human rest/activity cycles through a wereable accelerometer. Data for rest/active period will be extracted through a dedicated software.

    Time frame: Baseline, Follow-up 1year, Follow-up 2year

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jul 2024, 24 months after the start.

Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 24 months is below that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Jan 23, 2024
StartActual
Jul 1, 2022
Primary completionEst.
Jul 7, 2024
CompletionEst.
Dec 2025
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06219291
Collaborators
IRCCS San Raffaele, Azienda Sanitaria Locale di Cagliari
Responsible party
Sponsor
First posted
Jan 23, 2024
Start date
Jul 1, 2022
Primary completion
Jul 7, 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jan 23, 2024

Study contacts

Marco Rovaris, MD
principal investigator · IRCCS Fondazione Don Carlo Gnocchi
Raffaella Chieffo, MD
principal investigator · IRCCS Ospedale San Raffaele
Eleonora Cocco, MD
principal investigator · Ospedale Binaghi ASL Cagliari, Sardegna

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion